Biohaven Stock Catapults On A Surprise FDA Move Why It Might Not Be Done Running
Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole.
ETH-4.56%
BTC-4.12%
SOL-4.48%
XRP-6.29%
USDC+0.04%
DOGE-5.69%
SUI-7.08%
HYPE-5.07%ETH-4.56%BTC-4.12%SOL-4.48%XRP-6.29%USDC+0.04%DOGE-5.69%SUI-7.08%HYPE-5.07%ETH-4.56%BTC-4.12%SOL-4.48%XRP-6.29%USDC+0.04%DOGE-5.69%SUI-7.08%HYPE-5.07%ETH-4.56%BTC-4.12%SOL-4.48%XRP-6.29%USDC+0.04%DOGE-5.69%SUI-7.08%HYPE-5.07%
